Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 20/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 19/20 | 0.47 |
| ▸ | ITGB5 | P18084 | 7/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.46 |
| ▸ | ITGB6 | P18564 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4716436 | 0.92 | CXCR4 (0.43) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL4714670 | 0.90 | ITGAV (0.45) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL4715027 | 0.89 | ITGAV (0.48) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL14222270 | 0.89 | ITGAV (0.47) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL4715272 | 0.89 | ITGAV (0.49) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL14222264 | 0.89 | ITGAV (0.48) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL14221974 | 0.88 | ITGAV (0.51) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL4718218 | 0.88 | ITGAV (0.46) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL4791224 | 0.87 | ITGAV (0.57) | ITGAVITGB3ITGB5ITGA2BITGB6 | |
| SCHEMBL4789561 | 0.87 | ITGAV (0.57) | ITGAVITGB3ITGB5ITGA2BITGB6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | claimed |
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |